Interaction of Antiphospholipid Antibodies with Endothelial Cells

  • N. Del Papa
  • E. Raschi
  • A. Tincani
  • P. L. Meroni


The presence of circulating anti-phospholipid antibodies (aPL) is associated with a thrombophilic diathesis [1]. Among the proposed mechanisms by which aPL might cause thrombi formation, investigators have considered the relationship between aPL and the surface membranes of cells involved in the coagulation cascade, namely platelets and endothelial cells (EC) [2].


Human Umbilical Vein Endothelial Cell Brain Endothelial Cell Human Umbilical Vein Endothelial Cell Monolayer Hughes Syndrome Endothelial Cell Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hughes GRV. Hughes’ syndrome: The anti-phospholipid syndrome. A historical view. Lupus 1998; 7 (Suppl): S1–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7 (Suppl): S114–119.PubMedCrossRefGoogle Scholar
  3. 3.
    Cines D, Pollak E, Buck C et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527–3561.PubMedGoogle Scholar
  4. 4.
    Carreras LO, Vermylen JG. Lupus anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38–40.PubMedGoogle Scholar
  5. 5.
    Carreras LO, Martinuzzo MO. The lupus anticoagulant and eicosanoids. Prostagland Leukotr Ess Fatty Acids 1993; 49: 483–488.CrossRefGoogle Scholar
  6. 6.
    Carreras LO, Martinuzzo MO, Maclouf J. Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase-2. Lupus 1996; 5 (Suppl): 494–497.PubMedGoogle Scholar
  7. 7.
    Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A et al. Antiphospholipid antibodies and endothelial cells. Clin Exp Immunol 1988; 74: 247–253.PubMedGoogle Scholar
  8. 8.
    Hasselaar P, Derksen RHW, Blokzjil L, De Groot PG. Cross-reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 1990; 63: 169–173.PubMedGoogle Scholar
  9. 9.
    Del Papa N, Meroni PL, Tincani A, Harris EN, Pierangeli SS, Barcellini W et al. Relationship between antiphospholipid and antiendothelial antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992; 10: 37–42.PubMedGoogle Scholar
  10. 10.
    Le Roux G, Wautier MP, Guillevin L, Wautier JL. IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemost 1986; 56: 144–146.PubMedGoogle Scholar
  11. 11.
    Rosenbaum J, Pottinger BE, Woo P, Black CM, Louzou S, Byron MA et al. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988; 72: 450–456.PubMedGoogle Scholar
  12. 12.
    McCrae KR, De Michele A, Samuels P, Roth D, Kuo A, Meg QH et al. Detection of endothelial cell reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 1991; 79: 595–605.PubMedCrossRefGoogle Scholar
  13. 13.
    Del Papa N, Conforti G, Gambini D, Barcellini W, Borghi MO, Fain C et al. Characterization of anti-endothelial cell antibodies in anti-phospholipd syndrome. In: Polli EE, editor. Molecular bases of human diseases. Amsterdam: Excerpta Medica, 1993; 67–74.Google Scholar
  14. 14.
    Cervera R, Khamashta MA, Font J, Ramirez J, D’Cruz D, Montalban J et al. Anti-endothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991; 11: 1–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vasquez JJ et al. Immune mediated mechanisms for thrombosis: anti-phospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 849–852.PubMedCrossRefGoogle Scholar
  16. 16.
    Del Papa N, Conforti G, Gambini D, La Rosa L, Tincani A, D’Cruz D et al. Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopatho1 1994; 70: 211–216.CrossRefGoogle Scholar
  17. 17.
    Le Tonquèze M, Salozhin K, Dueymes M, Piette JC, Lovalev V, Shoenfeld Y et al. Role of b2-glycoprotein I in the anti-phospholipid antibody binding to endothelial cells. Lupus 1995; 4: 179–186.PubMedCrossRefGoogle Scholar
  18. 18.
    McIntyre J.A. Immune recognition at the maternal-fetal interface: overview. Am J Reprod Immunol 1992; 28: 127–131.PubMedGoogle Scholar
  19. 19.
    La Rosa L, Meroni PL, Tincani A, Balestrieri G, Faden A, Lojacono A et al. β2-glycoprotein I and placental anti-coagulant protein I in placentae from patients with anti-phospholipid syndrome. J Rheumatol 1994; 21: 1684–1698.PubMedGoogle Scholar
  20. 20.
    Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A et al. Relationship between antiphospholipid and anti-endothelial antibodies III: β2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13: 179–186.PubMedGoogle Scholar
  21. 21.
    Kandhia DA, Krilis SA. Beta2-glycoprotein. Lupus 1994; 3 (Suppl): 207–212.CrossRefGoogle Scholar
  22. 22.
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K et al. Endothelial cell as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551–561.PubMedCrossRefGoogle Scholar
  23. 23.
    Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141–2149.PubMedCrossRefGoogle Scholar
  24. 24.
    Hunt JE, Krilis SA. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys 281-Cys 288) and a region recognized by anti-cardiolipin antibodies. J Immunol 1994; 152: 653–661.PubMedGoogle Scholar
  25. 25.
    Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis S. Site-directed mutagenesis of recombinant human β2glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744–3751.PubMedGoogle Scholar
  26. 26.
    Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2-glycoprotein I antibodies. J Immunol 1998; 160: 5572–5578.PubMedGoogle Scholar
  27. 27.
    Coull BM, Levine SR, Brey RL. The role of anti-phospholipid antibodies and stroke. Neurol Clin 1992; 10: 125–143.PubMedGoogle Scholar
  28. 28.
    Fajardo LF. The complexity of endothelial cells. Am J Pathol 1989; 92: 241–250.Google Scholar
  29. 29.
    Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 14: 673–683.Google Scholar
  30. 30.
    Hess DC, Shepard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with aPL. Stroke 1993; 24: 994–999.PubMedCrossRefGoogle Scholar
  31. 31.
    Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211–2219.PubMedCrossRefGoogle Scholar
  32. 32.
    George J, Blank M, Levy Y, Meroni PL, Damianovich M, Tincani A et al. Differential effects of anti-beta 2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 900–906.PubMedCrossRefGoogle Scholar
  33. 33.
    Nawrot P, Stern D. Endothelial cell procoagulant properties and the host response. Semin Thromb Hemost 1987; 13: 391–398.CrossRefGoogle Scholar
  34. 34.
    Kaplanski G. Increased serum soluble VCAM-1 in the anti-phospholipid syndrome. Lupus 1996; 5 (Suppl): S548 (abstract).Google Scholar
  35. 35.
    Carlos TM, Harlam JM. Leukocyte-endothelial adhesion molecule. Blood 1994; 84: 2068–2101.PubMedGoogle Scholar
  36. 36.
    Pierangeli S, Colden-Stanfield M, Liu X, Harris EN. Antiphospholipid antibodies activate endothelial cells in vitro and in vivo. Lupus 1998; 7 (Suppl): S179 (abstract).Google Scholar
  37. 37.
    Habib A, Martinuzzo M, Carreras LO, Levy-Toledano S, Maclouf J. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Thromb Haemost 1995; 74: 770–777.PubMedGoogle Scholar
  38. 38.
    Lellouche F, Martinuzzo ME, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894–2899.PubMedGoogle Scholar
  39. 39.
    Atsumi T, Khamashta MA, Haworth RS, Brooks G, Amengual O, Ichikawa K et al. Arterial disease and thrombosis in the anti-phospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998; 41: 800–807.PubMedCrossRefGoogle Scholar
  40. 40.
    Goldman D, Philips G, Back K, Petri M. Binding of SLE antibodies on apoptotic cells. Arthritis Rheum 1995; 38 (Suppl): S214 (abstract).Google Scholar
  41. 41.
    Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207–2215.PubMedGoogle Scholar
  42. 42.
    Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced pro-coagulant activity implications for coagulation events and antigenic spread in SLE. Proc Natl Acad Sci USA 1996; 93: 1624–1629.PubMedCrossRefGoogle Scholar
  43. 43.
    Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 40: 205–214.CrossRefGoogle Scholar
  44. 44.
    Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2-glycoprotein I. Arthritis Rheum 1998; 40 (2): 215–222.CrossRefGoogle Scholar
  45. 45.
    Rouch J, Subang R, Koh JS, Levine JS. Induction of anti-phospholipid antibodies by 1.32-glycoprotein I bound to apoptotic thymocytes. Lupus 1998; 7 (Suppl.): 66.Google Scholar
  46. 46.
    Nakamura N, Shidara Y, Kawaguchi N, Azuma C, Mitsuda N, Onishi S et al. Lupus anticoagulant autoantibody induces apoptosis in HUVEC: involvement of annexin V. Biochem Byophis Res Commun 1994; 205: 1488–1493.CrossRefGoogle Scholar
  47. 47.
    Bordron A, Dueymes M, Levy Y, Jamin C, Ziporen L, Piette JC et al. Anti-endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies. Arthritis Rheum 1998; 41: 1738–1747.PubMedCrossRefGoogle Scholar
  48. 48.
    Rand JH, Wu XX, Andree HAM, Lockwood CJ, Guller S., Scher J et al. Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154–160.PubMedCrossRefGoogle Scholar
  49. 49.
    Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444–1454.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2000

Authors and Affiliations

  • N. Del Papa
  • E. Raschi
  • A. Tincani
  • P. L. Meroni

There are no affiliations available

Personalised recommendations